TGA deploys Post Market Review Compliance Dashboard

29 October 2020 |

shutterstock_482109052 (1)

Under the Therapeutic Goods Act 1989, it is mandatory for sponsors and manufacturers to report adverse events that have, or could have, led to death, serious illness or injury to a patient or device users or others.

Manufacturers are aware that adverse events can trigger a post-market review by the Therapeutic Good Administration (TGA). These reviews help determine if the device continues to meet safety and performance requirements and to ensure the sponsor is in compliance with the conditions of ARTG Inclusion.

TGA reviews may result in several outcomes:

  • improvements to the supporting documentation;
  • a need for design change; or
  • suspension or cancellation of the device from the ARTG.

Any of these can also trigger post-market action, including safety alerts or device recalls. Following the increase in post-market surveillance, it is critically important that all manufacturers, sponsors and distributors are fully aware of their obligations under the Act.

Effective Monday, 19 October 2020, the TGA deployed a new Post Market Review Compliance Dashboard, developed to improve accessibility and capability in the post-market monitoring of medical devices.

The dashboard, accessed through eBS, allows sponsors to view and respond to notifications efficiently and securely using a central location. Sponsors may upload relevant files (up to 15GB per file), without the need to send files via the Cloud, email, or mailing USBs to different teams at the TGA.

To assist sponsors with proper usage of the dashboard in responding to notifications (including requests for information, proposals to cancel or suspend notifications, or on conditions of inclusion) TGA has made available a Reference Guide providing step-by-step instructions. In addition, webinars providing further guidance in training sessions were also held during October 2020.

In June 2020, besides developing demonstrations and training guidelines in preparation for implementation, the TGA sought participation from select sponsors to test the functionality and ease of use of the dashboard and provide feedback. Brandwood CKC participated in this testing and validation and found the dashboard to be very user-friendly.

Our consultants are well versed in post-market compliance requirements based on their local experience and knowledge – please reach out to our regulatory experts to provide assistance and support in all your post-market activities.

We offer deep support for navigating international regulatory processes.  Whether it’s a TGA application, a strategy for MDR transition, a US presubmission or 510(k) filing, or specific help with regulatory documents (e.g. Clinical Evaluation Reports), or an update of your quality system to gain MDSAP. We understand you need a commercial approach which delivers viable options. Reach out today and start a conversation. Contact us to discuss your needs and how we can help. You can drop us an email [email protected] or call 1 888-271-5063 (US toll free) ♦ +61 2 9906 2984 (Sydney)

Disclaimer
The views and options expressed in this article are those of the author/s and do not necessarily reflect the views of Brandwood CKC Pty Ltd ACN 128 762 505.

The information presented in this article is of a general nature only and does not consider the particular circumstances of your business. Prior results and case studies do not guarantee a similar outcome in future. You should not rely on this information, and you should seek specific advice for your particular business needs.

Where indicated, certain content has been sourced from third parties; we have not independently verified it. Neither Brandwood CKC nor the author makes any warranty as to the accuracy, completeness or reliability of this article, nor do those parties accept any liability or responsibility arising in any way from omissions or errors contained in the content.

Search

Recent Posts

Categories

Categories

Archives

Archives

Archives